NCT07637851
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07637851
Title Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer (RegeNovar)
Acronym RegeNovar
Recruitment Not yet recruiting
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors ARCAGY/ GINECO GROUP
Indications
Therapies
Age Groups: senior | adult
Covered Countries FRA

Facility Status City State Zip Country Details
Institut Bergonié Bordeaux 33076 France Details
Centre François Baclesse Caen 14076 France Details
Centre Georges François Leclerc Dijon 21079 France Details
Centre Léon Bérard Lyon 69373 France Details
Institut Paoli Calmettes Marseille 13273 France Details
ICM Val d'Aurelle Montpellier 34298 France Details
HCL - Centre Hospitalier Lyon Sud Pierre-Bénite 69495 France Details
Centre Eugène Marquis Rennes 35042 France Details
ICO - Centre René Gauducheau Saint-Herblain 44805 France Details
Hôpital de Hautepierre Strasbourg 67098 France Details
Gustave Roussy Villejuif 94805 France Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field